The metabolic genes isocitrate dehydrogenase 1 (IDH1) and IDH2 are commonly mutated in low-grade glioma and in a subset of glioblastoma. These mutations co-occur with other recurrent molecular alterations, including 1p/19q codeletions and tumor suppressor protein 53 (TP53) and alpha thalassemia/mental retardation (ATRX) mutations, which together help to define a molecular signature that aids in the classification of gliomas and helps to better predict clinical behavior. A confluence of research suggests that glioma development in IDH-mutant and IDH wild-type tumors is driven by different oncogenic processes and responds differently to current treatment paradigms. Herein, the authors discuss the discovery of IDH mutations and associated molecular alterations in glioma, review clinical features common to patients with IDH-mutant glioma, and highlight current understanding of IDH mutation-driven gliomagenesis with implications for emerging treatment strategies. Cancer 2017;123:4535-46.
INTRODUCTION
Gliomas are infiltrative primary brain tumors that account for approximately one-third of all central nervous system tumors. 1 Gliomas traditionally have been categorized by the World Health Organization (WHO) grading system into 4 histopathologic grades, denoted as I to IV, which describes them in terms of histopathologic lineage as either astrocytoma, oligodendroglioma, or oligoastrocytoma. 2 The majority of adult gliomas are noted to be grades II to IV, with higher grades generally noted among patients of more advanced age and conferring a less favorable prognosis.
Importantly, the last decade has witnessed major advances in the genomic characterization of many cancer types, and adult glioma has proven to be no exception. The identification of several key molecular markers, most notably isocitrate dehydrogenase (IDH) mutations, has allowed for a more granular method with which to categorize glial tumors with clear prognostic implications. It is now well-appreciated that IDH mutations help to define a class of low-grade gliomas with behavior that is distinct from their IDH wild-type counterparts. In this review article, we describe the discovery of the IDH mutation and how it has shaped our clinical characterization of gliomas, review the current biology of IDH enzymes and their role in tumorigenesis, and discuss the implications of IDH mutations on future treatment strategies.
Discovery of IDH Mutations in Glioma
The connection between glioma and IDH mutations initially was discovered within the context of an exome sequencing study of glioblastoma, in which recurrent mutations in the IDH1 gene were noted in >20% of the tumors analyzed. 3 These samples demonstrated a heterozygous point mutation leading to a switch from arginine to histidine at amino acid 132. Further work demonstrated that mutations also occur in the IDH2 gene at an analogous arginine, at position 172, 4, 5 although the frequency of this mutation is much less common, accounting for <1% of all IDH mutations in patients with glioma. 5 Analysis of a wide range of brain tumors led to the discovery that IDH mutations are present in 80% to 90% of grade II and grade III gliomas, as well as in approximately 5% of glioblastomas. 3, 4, 6 The IDH1 R132H mutation is by far the most common in glioma, noted in >90% of cases, but noncanonical variants including R132C, R132S, R132G, and R132L also have been observed 5 and confer a similar change in IDH activity, 7 which will be discussed in more detail below. The correlation between IDH mutation and lower tumor grade inspired several groups to investigate the effect of IDH mutation on survival. In what to our knowledge was one of the initial analyses of IDH mutation in patients with glioma, a note was made of prolonged overall survival (OS) in patients with IDH-mutant tumors that fell in both the anaplastic astrocytoma and glioblastoma categories. 4 Further systematic analyses of larger cohorts confirmed this trend. In a retrospective analysis of 382 anaplastic astrocytomas and glioblastomas, Hartmann et al demonstrated that the presence of an IDH mutation was a stronger predictor of OS than histologic grade. 8 Similarly, in a group of 552 patients with WHO grade II and III astrocytomas, histologic grade was found to have a minimal impact on prognosis in both the IDH wild-type and IDH-mutant groups, but patients with IDH-mutant glioma lived a median of 3 times longer than those with IDH wild-type tumors. 9 Before the report of IDH mutations in glioma, mutations of this gene had to our knowledge otherwise only been implicated in a single case of colorectal cancer in the literature. 10 However, after this publication, subsequent reports identified IDH1 or IDH2 mutations in acute myelogenous leukemia, [11] [12] [13] cholangiocarciomas, 14 and chondrosarcoma, 15 also always affecting the conserved arginine at residue 132 or 172 in IDH1 or IDH2, respectively.
Normal IDH Enzyme Function
The IDH1 and IDH2 enzymes are located in the cytosol/ peroxisome and mitochondria, respectively, and promote the oxidative decarboxylation of isocitrate to alphaketoglutarate (a-KG). Both enzymes are structurally similar, nicotinamide adenine dinucleotide phosphate (NADP 1 )-dependent, and function as homodimers. The production of the critical reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) by IDH1 and IDH2 is believed to help protect the cell from reactive oxygen species (ROS), which can cause DNA damage. 16, 17 In addition, a-KG generated by IDH1 activity has been shown to serve as a cofactor for several important cellular reactions, including histone modifications, hypoxia sensing, and fatty acid metabolism. 18, 19 The reaction catalyzed by IDH1 is reversible, particularly in the setting of hypoxia, and the IDH1-dependent reductive carboxylation of a-KG to isocitrate can be funneled into a lipogenesis pathway. 20 In contrast to IDH1, the functional role of IDH2 is less clear. IDH2 is presumed to function in the tricarboxylic acid (TCA) cycle, although the bulk of a-KG to isocitrate conversion is believed to be performed by the structurally unrelated, nicotinamide adenine dinucleotide (NAD 1 )-dependent enzyme IDH3 (Fig. 1A) .
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Implications of the IDH Mutation on Enzyme Function
The recurrent driver mutations noted at arginine 132 in IDH1 and arginine 172 in IDH2 are located within the active site of the enzyme and therefore have been (A) Isocitrate dehydrogenase 1 (IDH1) and IDH2 (red) perform their enzymatic functions in the cytosol and mitochondria, respectively. Within the context of the tricarboxylic acid cycle (TCA) (right), the reduction of isocitrate to a-ketoglutarate is performed by both IDH2 (red) and IDH3. Reversibility of the wild-type IDH1 reactions allows IDH1 to function as part of the glutamine aneuplerosis pathway. (B) Biochemical reactions catalyzed by wild-type and mutant IDH1 (IDH1mut) and IDH2 (IDH2mut) enzymes. The wild-type enzyme normally promotes the nicotinamide adenine dinucleotide phosphate (NADP implicated in altering the function of the enzyme. The mutation occurs in a heterozygous fashion, and an initial report of the functional consequence of the R132H mutation suggested that the heterodimeric protein composed of IDH1 wild-type and IDH1 R132H is nonfunctional. 22 However, thinking regarding the functional consequences of the mutation changed when Dang et al 7 reported that glioma cells engineered to overexpress IDH1 R132H produced high levels of D-2-hydroxyglutarate (D-2HG). This metabolite, and its enantiomer L-2-hydroxyglutarate, normally are present at low levels within the cell but the study by Dang et al suggested that the mutant IDH1 acquires a neoenzymatic activity, which leads to additional catalysis of a-KG to D-2HG (Fig. 1B) . 7 It is interesting to note that they found that IDH-mutant enzyme exclusively produces the D-2HG enantiomer. 7 Although excess D-2HG is produced only by mutant IDH tumors, L-2HG can accumulate to high levels in the setting of hypoxia.
There are several proposed functional consequences of D-2HG accumulation. Both enantiomers of 2HG can competitively inhibit the large family of a-KG-dependent dioxygenases, 23 which are involved in a diverse range of cellular processes. These enzymes use oxygen, iron, and ascorbate as cofactors, tying nutrient sensing to the regulation of many cellular processes. 23, 24 Perhaps the most notable members of the a-KG-dependent dioxygenases are the ten-eleven translocation (TET) enzyme family of 5 methylcytosine (5mC) hydroxylases and JumonjiC (JmjC) domain-containing histone demethylases, both of which are involved in maintenance of the cellular epigenetic state. In addition, D-2HG, but not L-2HG, can stimulate the activity of the Egl nine homolog (EGLN) prolyl-hydroxylases involved in hypoxia signaling, leading to decreased hypoxia-inducible factor (HIF) levels and increased tumor proliferation and growth. 25 Finally, elevated 2HG levels have been implicated in the production of high levels of ROS, 26 possibly because of disruption of the NAPD/NAPDH balance during 2HG generation. Elevated ROS has been linked to mutagenesis and tumorigenesis. 27 
Proposed Role of IDH in Tumorigenesis
Changes in epigenetic regulation
To the best of our knowledge, the exact manner by which mutant IDH1 or IDH2 can promote gliomagenesis remains unclear, but a confluence of work has provided several possible explanations. Tumor evolution studies involving the sequencing of paired initial and recurrent IDH-mutant tumors have suggested that mutation of the IDH gene is an early event in tumor formation, as evidenced by a consistently high mutant allele fraction at the time of diagnosis and disease recurrence. 28 These data support the theory that mutant IDH function is directly responsible for oncogenesis. Some forms of glioma exhibit a specific global methylation pattern at CpG islands, referred to as glioma CpG island methylator phenotype (G-CIMP). 29 This altered epigenetic state influences which genes are being expressed or silenced and is believed to play a critical role in tumorigenesis. The G-CIMP pattern was found to be correlated with a particular gene expression pattern known as the proneural subtype, noted in expression profiling studies of samples in The Cancer Genome Atlas. 30 As further work revealed that the proneural subtype essentially overlapped with the IDHmutant group of tumors, investigators became interested in whether the IDH mutation played a direct role in establishing the signature hypermethylation pattern. Indeed, Turcan et al demonstrated that expression of IDH1 R132H in normal human astrocyte reshaped the methylome to create the G-CIMP signature. 31 Similarly, the treatment of cell cultures with exogenous D-2HG also could create a repressive methylation pattern, 32 further strengthening the causative role of D-2HG in glioma development. In these in vitro models, the epigenetic changes become most prominent and stable in later passages, suggesting that this is a slowly occurring event. 31 The relationship between IDH mutation, elevated 2HG, and the altered methylome is strengthened by the ability of 2HG to inhibit a-KG-dependent dioxygenases. a-KG-dependent dioxygenases are critical for epigenetic regulation. In particular, DNA methylation at cytosine residues is in part regulated by the a-KG-dependent TET family of demethylases. TET enzymes are sensitive to oxygen conditions and the activity of these enzymes decreases in the setting of hypoxia; it is interesting to note that the pattern of hypermethylated genes that occurs with hypoxia overlaps considerably with that of IDH-mutant glioblastoma, although the overall amount of hypermethylation is significantly more in IDHmutant tumors compared with that found in hypoxic tumors. Likewise, histone methylation on lysines is regulated by a-KG-dependent JmjC demethylases. An increase in repressive histone methylation marks have been observed in IDH-mutant cell lines, and these histone marks, particularly at H3K9, appear to occur earlier than global DNA hypermethylation in an in vitro IDHmutant tumor cell model, 32 suggesting that repressive histone conformation in turn leads to DNA hypermethylation. Overall, this leads to an attractive theory for IDHmutant-induced gliomagenesis, which purports that IDH-driven epigenetic changes allow glioma cells to remain in a less differentiated or stem-like state, rendering them vulnerable to acquiring additional oncologic insults, such as tumor suppressor protein 53 (TP53) mutations or loss of heterozygosity at chromosomes 1p and 19q. Furthermore, there is evidence that overexpression of IDH1 R132H in normal human astrocyte cell culture can promote proliferation and colony formation. 25 The ability of the IDH mutation to transform cells appears to be dependent on 2HG production because a small molecule that efficiently lowers 2HG levels abolishes this activity. 33 It is interesting to note that IDH1-mutant-associated hypermethylation recently was shown to occur at cohesion and CCCTC-binding factor (CTCF)-binding sites, which play a role in the formation of chromatin loops and in the maintenance of chromosomal topology. 34 Normally, CTCF-binding proteins serve as insulators to help create boundaries between different parts of the genome. If CTCF boundaries are disrupted by the inability of CTCF proteins to bind, as in the case of methylation of these sites, aberrant gene expression may occur through abnormal enhancer gene interactions. Bernstein et al proposed that disrupted CTCF-binding secondary to IDH-mutant-induced hypermethylation leads to a loss of insulation at critical regions that permit a constitutive gene enhancer to be in proximity of potential oncogenes, with aberrant platelet-derived growth factor receptor (PDGFR) signaling as one candidate example. 34 
Changes in metabolism
The IDH enzymes play important roles in the biosynthesis of central metabolites of the TCA cycle. IDH1 in particular sits at a lymph node that allows for determination of the direction of the TCA cycle. Wild-type IDH1 can catalyze both the so-called "forward" or oxidative reaction of isocitrate to a-KG as well as the "reverse" or reductive reaction (a-KG to isocitrate) under conditions of stress. 20 This permits glutamine to be converted to citrate for fatty acid synthesis. However, IDH1 R132H mutant enzyme has reduced capacity to promote reductive carboxylation, thereby rendering the cell more dependent on the "forward" reaction of the TCA cycle and mitochondrial oxidative respiration for the production of precursors for fatty acid synthesis (Fig. 1A) . 35 These data suggest that IDH-mutant glioma may be particularly susceptible to hypoxia or conditions leading to mitochondrial dysfunction.
In addition to the production of large levels of D-2HG, other intracellular metabolites also are altered in IDH-mutant gliomas. For example, nicotinamide adenine dinucleotide (NAD1/NADH) is found at much lower levels in IDH-mutant glioma compared with IDH wildtype gliomas, 36 and this likely has functional consequences on both metabolism and cellular signaling processes. Low basal levels of NAD1/NADH appear to result from decreased biosynthesis as a result of methylation-dependent decreased expression of the NAD 1 salvage pathway enzyme nicotinate phosphoribosyltransferase (Naprt1). It is interesting to note that the decreased ability to synthesize NAD1/NADH renders IDH-mutant glioma vulnerable to further NAD1/ NADH depletion through inhibition of the alternative NAD synthetic enzyme nicotinamide phosphoribosyltransferase (NAMPT). 36 
IDH Mutations Help to Define Low-Grade Glioma
IDH mutations are present in the majority of low-grade glioma cases, regardless of histologic subtype. 5 Additional recurrent molecular alterations have been noted that, in conjunction with IDH mutations, have allowed for a refined classification system that uses both a histologic and a molecular signature. The combined work of numerous investigations has led to the emergence of 2 major genetic subtypes.
Tumors of oligodendroglial lineage demonstrate allelic loss of chromosome 1p and 19q (1p/19q codeletion) 37, 38 in addition to the IDH mutation, and this allelic loss is associated with a favorable prognosis and improved OS 39 compared with tumors without 1p/19q codeletion. The important candidate genes that are lost when these specific chromosome regions are deleted are emerging, most notably the homolog of Drosophila capicua (CIC), which has been found to be mutated in up to 50% of oligodendroglial tumors 40 and whose function to the best of our knowledge remains largely unclear. The majority of oligodendroglial tumors also display abnormal telomerase activity through the acquisition of mutations in the telomerase reverse transcriptase (TERT) promoter. 41 It is interesting to note that a molecular analysis of >1000 tumors from multiple centers noted a small subset (<3%) of these tumors exhibited an IDH mutation and 1p/19q codeletion without TERT mutation. 42 Interestingly, IDH wild-type glioblastoma also appear to exhibit TERT promoter mutations.
In contrast, astrocytic tumors do not typically exhibit TERT promotor mutations but rather maintain telomere length through a process termed "alternative lengthening of telomeres." In astrocytomas, this appears to be accomplished by mutation of the alpha thalassemia/ mental retardation (ATRX) gene, which encodes for a protein involved in chromatin remodeling at telomeres. ATRX mutations have been found in 86% of IDH-mutant tumors in which 1p/19q is not deleted, [42] [43] [44] and appear to be mutually exclusive with TERT promoter mutations.
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TP53 mutations have long been associated with tumors with astrocytic histology and are observed at a frequency of 83% in these tumors, as well as are associated with IDH mutation and maintenance of 1p/19q. 42 Furthermore, an analysis of >300 brain tumors revealed a very high frequency of co-occurrence of ATRX mutation and TP53 mutation. 44 Synthesizing the molecular characteristics together, 3 tumor subtypes emerge: 1) IDH-mutant tumors with 1p/19q codeletion and TERT promoter mutation, associated with oligodendroglial histology; 2) IDH-mutant tumors with 1p/19q maintained, TP53 mutations, and ATRX mutations, usually associated with astrocytic histology; and 3) IDH wild-type tumors with TERT promoter mutation, also often appearing astrocytic (Fig. 2) . It is interesting to note that the molecular grouping of tumors often aids in predicting their clinical behavior better than histologic grading. Indeed, work by Jiao et al and later The Cancer Genome Atlas Research Network as well as
Eckel-Passow et al demonstrated that shared clinical characteristics and prognostic patterns emerge that allow for the more accurate prediction of tumor aggressiveness, 42, 44, 45 which will be discussed in further detail. Consequently, the update of the fourth edition of the WHO Classification of Central Nervous System Tumors now uses both the histopathologic diagnosis and molecular diagnosis, using IDH and 1p/19q status to create a combined integrated diagnosis. 2 It is interesting to note that, although helpful for making an integrated pathologic diagnosis, analysis of TP53 and ATRX are not required for classification by WHO criteria.
Clinical Features of IDH-Mutant Glioma
Low-grade glioma typically affects a younger population than high-grade glioma/glioblastoma. 1 The emergence of molecular subtyping of these tumors has revealed clear patterns in their epidemiology and prognosis. Patients with tumors containing mutations in IDH, TP53, and ATRX (astrocytic tumors) are diagnosed at a median age of 34 years whereas patients whose tumors have the molecular signature of IDH mutation, 1p/19q codeletion, and TERT promoter mutation (oligodendroglial tumors) generally are a decade older at the time of diagnosis. 42, 44, 45 The age at the time of diagnosis of patients with IDH wild-type glioma is older than either of the IDH-mutant groups. IDH-mutant tumors tend to be more preferentially located anatomically in the frontal lobes compared with other lobes, [45] [46] [47] and compared with IDH wild-type tumors. 45, 48 There also is evidence that IDH-mutant tumors may be less likely to be found in high-risk surgical areas. 48 In a review of 335 malignant gliomas, the IDH mutation was found to be independently associated with a complete surgical resection compared with IDH wildtype tumors, 46 suggesting that some characteristics of IDH-mutant tumor biology render them more amenable to complete surgical tumors.
IDH-mutant tumors often are able to be distinguished radiologically from IDH wild-type tumors by enhancement patterns. IDH-mutant tumors do not usually take up contrast unless they are of a higher grade or recurrent. 46, 48 The observation of less contrast enhancement in IDH-mutant tumors is believed to be driven primarily by the integrity of the blood-brain barrier, which is more intact than in patients with IDH wild-type gliomas. This is supported by report of hypoperfusion in IDHmutant gliomas. 49 Decreased permeability of the bloodbrain barrier may be related to the inhibition of angiogenesis in IDH-mutant glioma. 50, 51 The most striking clinical correlation that reinforced the theory that IDH-mutant gliomas behave differently is the finding that patients with an IDH-mutant glioma live longer than patients with IDH wild-type glioma. There were hints of this survival advantage when recurrent IDH1 mutations were first reported in 2008 by Parsons et al, in which the authors noted that the patients with IDH-mutant glioblastoma survived a median of 31 months compared with 15 months in patients with IDH wild-type glioblastoma. 3 Similarly, the median OS of patients with grade III IDH-mutant glioma was 65 months compared with 20 months in patients with IDH wild-type glioma. 4 This trend now has been observed by many groups. Furthermore, the survival patterns also can be refined by subgrouping by oligodendroglial, astrocytic, or glioblastoma molecular signatures. Within the realm of IDH-mutant tumors, patients with oligodendroglial tumors, which bear 1p/19q codeletion and TERT promoter mutations, enjoy the best prognosis, with a median OS of 8 years, compared with a median OS of 5 years for patients with astrocytic tumors with IDH, TP53, and ATRX mutations. 44 It is important to note that these OS determinations were made using a cohort of patients who were treated heterogeneously.
It also has become apparent that a tumor's IDH mutation status is a stronger determinant of prognosis than its histological grade. Specifically, in an analysis of grade II and grade III gliomas with and without IDH mutation, the tumor grade was found to have little bearing on OS in the IDH-mutant population. However, in the study by Olar et al, the tumor grade and mitotic index did correlate with prognosis in patients with IDH wildtype tumors. 9 Likewise, in patients with higher grade glioma, it has been shown that the most favorable outcomes are found in those with IDH-mutant grade III glioma and IDH-mutant glioblastoma, followed by IDH wild-type grade III glioma and glioblastoma. 8 Tumor grade continues to play a role in prognosis within each IDH subgroup, because patients with grade II IDH-mutant tumors tend to live longer than patients with IDH-mutant glioblastoma. 42 
Novel Methods of Detection of IDH-Mutant Tumors
The specificity of elevated levels of 2HG for either IDH1-mutant or IDH2-mutant tumors has inspired many to investigate methods with which to use this metabolite as a biomarker of IDH-mutant tumors by noninvasive means to monitor disease progression or treatment response. To our knowledge, no correlation between serum 2HG levels and the presence of an IDH mutation has been found in glioma. However, in a study of 2HG levels in the urine of a cohort of patients with both IDH wild-type and IDHmutant disease, urinary 2HG was found to be significantly higher in patients with IDH-mutant glioma. 52 It is not clear how reliable or robust urine 2HG levels are in patients with glioma, and we await future studies to determine whether this has potential as a future biomarker.
The high level of accumulation of 2HG also is being used for the detection of IDH-mutant tumors using in vivo magnetic resonance spectroscopy (MRS). This method was reported in 2012 in a series of articles from 3 independent groups demonstrating that 2HG detection in single-voxel MRS is possible. [53] [54] [55] However, these studies demonstrated a large number of false-positive results with conventional MRS, which can be significantly improved with spectral editing techniques. The technology is being developed further for use with a 3-dimensional MRS imaging technique. MRS for 2HG offers an attractive method with which to monitor IDHmutant tumors longitudinally, particularly when examining treatment response or distinguishing between tumor progression and treatment effect. A longitudinal study of patients with IDH-mutant tumors undergoing treatment demonstrated a significant decrease in 2HG levels detected by MRS, and this correlated with clinical and radiologic response by conventional magnetic resonance imaging. 56 Work currently is being done to optimize 2HG-based imaging for use in clinical practice and as a clinical trial endpoint. 57 Several challenges must be overcome before the technique can be used widely. Conventional short-echo MRS has shown to result in a false-positive rate of 25% to 30%. 55 Several 2HG-edited MRS methods have been proposed to increase the specificity of 2HG detection by MRS. 53, 54, 56, [58] [59] [60] Some of these methods have been evaluated in larger studies that demonstrated that specificity and sensitivity vary according to institution. 57, 61 In the study by de la Fuente et al, 57 detection of 2HG by MRS depended on the tumor size (91% true-positive rate for tumors measuring >8 cm 3 ), and in the studies by Choi et al 61 and Jafari-Khouzani et al, 62 a conservative threshold of >1 mM was found to classify gliomas as having mutant IDH. However, the sensitivity of MSR is not solely dictated by the tumor size, but by the density of mutant IDH cells and the efficiency of 2HG production. For example, in a tumor with an average concentration of 1 mM, a tumor volume of 8 cm 3 might be necessary, whereas in a tumor with an average concentration of 8 mM, a tumor volume of 1 cm 3 would be enough for the detection of 2HG on MRS. In addition to tumor size and intrinsic 2HG levels, spectral quality such as good spectral resolution (eg, linewidth of < 6 Hz at 3T), clean baseline, and no artifacts influence the ability to reliably detect 2HG by MRS. In spectra of very good quality, the lower limit of 2HG detection can be <1.1 mM. More validation of 2HG detection on MRS with gold-standard mass spectrometry 2HG measurements in a stereotactically registered biopsy is necessary to provide a clinical protocol with uniform performance across institutions, and more technical development could potentially push the limits of MRS detection of 2HG.
Clinical Management of Patients With IDHMutant Glioma
The treatment of gliomas involves some combination of surgical resection, radiotherapy (RT), and chemotherapy. The first step in the management of all patients with intracranial gliomas typically is surgery, with the dual aim of tissue diagnosis and tumor resection. In patients with IDH-mutant glioma, the establishment of a pathologic and molecular diagnosis is critical for the accurate prediction of clinical behavior, as discussed in detail above. In addition, in patients with low-grade glioma, there is clear evidence that maximal resection of nonenhancing tumor is associated with improved OS. 63 In light of the evidence that >80% of low-grade gliomas carry an IDH mutation, it perhaps is no surprise that this survival benefit has been shown to be very dependent on the presence of an IDH mutation. Indeed, complete resection of total tumor volume, defined as enhancing plus nonenhancing disease on magnetic resonance imaging, was found to be significantly associated with a longer OS in patients with IDH-mutant disease but not those with IDH wild-type glioma. 46 IDHmutant gliomas also are more amenable to macroscopic total resection, 46 and have very low rates of long-term postoperative neurological deficits. 63 For many years, the optimal postoperative management of low-grade gliomas has been under debate. The prolonged OS noted for patients with grade II and grade III glioma, compared with glioblastoma multiforme, raises concerns about the long-term side effects from the mainstay treatment modalities of RT and chemotherapy, particularly on a patient's functional and cognitive performance. In a study of patients with low-grade glioma who received either early RT at a dose of 54 gray (Gy) or RT deferred to the time of disease progression (European Organization for Research and Treatment of Cancer [EORTC] 22845), an improvement in progression-free survival but not OS was demonstrated. 64 This led some in the field to favor delaying aggressive treatments such as RT until the time of tumor recurrence, with the hope of minimizing the effects of delayed toxicity. Furthermore, the German Neurooncology Working Group (NOA)-04 trial compared RT with treatment with either procarbazine, lomustine, and vincristine (PCV) or temozolomide (TMZ) in patients. In the long-term follow-up of this study of 318 patients with anaplastic glioma, there was no difference noted with regard to the activity of monotherapy with either RT or chemotherapy in any histological or molecular subgroup of patients with grade III gliomas, which included individuals with anaplastic astrocytomas, anaplastic oligodendrogliomas, and anaplastic oligoastrocytomas. 65 Despite the relative equivalence of monotherapy with either RT or chemotherapy, more and more data have emerged to suggest that patients with IDH-mutant glioma benefit greatly from upfront, aggressive treatment.
In 2013, Cairncross et al reported on the long-term follow-up results of Radiation Therapy Oncology Group (RTOG) 9402, a study comparing RT alone with RT with PCV in patients with anaplastic oligodendroglioma and anaplastic oligoastroctyoma. 66 It is interesting to note that patients with 1p/19q codeleted tumors survived twice as long with the combination therapy of RT (59.4 Gy)
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Cancer December 1, 2017 and PCV compared with RT alone, with a median OS of 14.7 years compared with 7.3 years. However, the survival benefit associated with combination therapy was not found among patients lacking 1p/19q codeletion. 66 At the same time, investigators with the phase 3 EORTC 2651 trial published similar results indicating that patients with anaplastic oligodendroglioma and 1p/19q codeletion derived a significant benefit from the addition of PCV chemotherapy to RT, although an increase in the median OS was noted in patients both with 1p/19q codeletion and without. 67 Because patients with glioma with 1p/19 codeletion nearly universally also carry a mutation in IDH1 or IDH2, the data from RTOG 9402 were reanalyzed after stratification by IDH mutation status, which was available for 72% of patients (210 of 291 patients). Similar to the analysis based on 1p/19q codeletion, patients with IDH mutations derived a substantial survival benefit from RT and chemotherapy compared with RT alone; the benefit from chemotherapy was not observed in patients with IDH wild-type tumors. 68 Together, these data demonstrate that RT followed by PCV is superior to the use of RT alone in patients with grade III, 1p/19q codeleted, IDH-mutated tumors. Likewise, the benefit of combination therapy has similarly now been demonstrated in patients with "high-risk" grade II glioma, in which the designation of high risk is conferred to patients aged >40 years or anyone who underwent less than a macroscopic total resection at the time of surgery. In the RTOG 9802 trial, the survival benefit from combined therapy was nearly double that of RT alone (OS of 13.3 years vs 7.8 years; hazard ratio, 0.59 [P 5 .003]). 69 Although tumor tissue only was available for analysis for IDH mutation status in approximately 45% of the cases, the magnitude of the treatment effect derived from the addition of PCV to RT was greatest in those patients with tumor containing the IDH1 R132H mutation (noted in approximately 60% of cases). 69 Taken together, these trials have been pivotal in emphasizing the importance of aggressive, upfront treatment with RT and chemotherapy in patients with IDHmutant grade II and grade III glioma, and this treatment regimen now is being designated as the standard of care. Given the strong effect from chemotherapy in these 2 trials, members of the neuro-oncology community wondered whether alkylating chemotherapy, either PCV or TMZ, given as monotherapy could demonstrate an OS benefit comparable to that of RT plus chemotherapy. The rationale for using chemotherapy alone involves deferring RT until the time of disease progression with the hope of minimizing or preventing the delayed, radiation-associated neurocognitive deficits. This strategy was examined in patients with anaplastic astrocytoma in the NOA-04 trial, in which treatment with RT at the time of diagnosis was compared with either PCV or TMZ. 70 The long-term follow-up of this trial, published in 2016, suggested that chemotherapy as monotherapy in the upfront setting is not superior to RT, regardless of the molecular subtype. 65 From these data, many have concluded that the lack of superiority in this setting suggests that chemotherapy monotherapy likely would be inferior to RT plus chemotherapy.
Currently, the primary outstanding question in the field concerns the optimal chemotherapy regimen. The major trials comparing RT with chemotherapy that used the PCV combination were initiated before the development of TMZ, an oral, monofunctional alkylating agent. TMZ currently is perhaps the most widely used chemotherapy for the treatment of glioma after a pivotal EORTC trial published in 2005, which demonstrated a survival benefit for patients with glioblastoma when added to 60 Gy of RT. 71 As an oral agent, TMZ is easy to administer, is much better tolerated, and has a better toxicity profile compared with PCV. These characteristics increase the likelihood that a patient will be able to complete the full chemotherapy regimen and derive the maximal benefit from the treatment. 72 The NOA-04 trial attempted to compare the 2 different regimens by randomizing patients in the chemotherapy arm to either PCV or TMZ. No difference in time to treatment failure was noted, but the trial lacked adequate power with which to detect a significant difference. RT with concurrent and adjuvant TMZ with 3) TMZ alone in patients with newly diagnosed WHO grade III anaplastic oligodendroglioma with 1p/19q codeletion. At the time of the interim analysis, the OS in the TMZ-alone arm was found to be significantly shorter than that of either treatment arm containing RT (hazard ratio, 9.2; P 5 .048), leading to closure of the TMZ-only treatment arm. 73 In addition to removing the third treatment arm, the trial also was redesigned to add PCV to the RT-only arm after the results of the RTOG 9402 and EORTC 26951 trials, which suggested that combination treatment is superior to RT alone. 74 In addition, the ongoing Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma (CATNON) trial (ClinicalTrials.gov identifier NCT00626990) is examining the possible benefit of concurrent and/or adjuvant TMZ when added to RT in patients with grade III glioma without 1p/19q deletion. The interim analysis, based on 221 events over a median of 27 months of follow-up, noted a statistically significant OS benefit for patients who received adjuvant TMZ compared with those who received RT alone. 75 These early results further reinforce the idea that the combination of RT and chemotherapy is more efficacious than the use of RT alone.
Although not comparing PCV with TMZ directly, this trial may allow for the performance of TMZ to be compared with historical data from trials using PCV.
Promising Therapeutic Strategies
The discovery of recurrent IDH mutations in glioma has changed our tumor classification system and led to acknowledgment that the underlying tumor biology of IDH-mutant and IDH wild-type gliomas is very different. As a consequence, there is a growing appreciation that these tumor types should not necessarily be treated the same. Several treatment strategies currently are on the horizon that will take advantage of what has been learned thus far regarding IDH-mutant gliomagenesis.
Much energy has been put into the development of inhibitors that specifically target IDH1 or IDH2 enzymes to decrease D-2HG production. Based on tumor sequencing studies, the IDH mutation appears to be an early event in glioma formation, 28, 47 and remains present throughout the life span of the tumor, given that the mutation is present at the time of disease recurrence as well. 28 The stability of the mutation over time and evidence that it is a truncal event has led to IDH activity being viewed as an attractive target. The IDH1-inhibiting molecule AG-5198, which was found in a small molecule screen, demonstrated the ability to decrease IDH1-mutant glioma cell growth in an in vitro model and in an IDH1-mutant xenograft in mouse. 33 Several IDH-targeting drugs currently are in early-phase clinical trials and are being explored in patients with recurrent IDH-mutant glioma, including AG-120 and IDH305, which are specific for IDH1 mutations; AG-221, which is specific for the IDH2 mutation; and AG-881, which is a pan-IDH1/2 inhibitor. Although objective responses have been reported in patients with hematologic malignancies who are being treated with AG-221, 76 to the best of our knowledge the efficacy of these inhibitors in patients with glioma remains to be seen. At the annual meeting of the Society for Neuro-Oncology, preliminary data were presented demonstrating that 14 of 22 patients with nonenhancing, recurrent IDH-mutant glioma who were treated with AG-120 achieved stable disease, as determined by volumetric measurements. 77 There are some concerns with this approach, however. Although IDH inhibitors universally appear to be efficient at lowering D-2HG levels, the inhibitors have shown mixed ability in inhibiting glioma growth and proliferation when tested in a variety of patient-derived glioma lines, 36, 78 thereby suggesting that D-2HG metabolite levels are not strictly correlated with tumor growth capacity. In contrast to the findings that higher levels of D-2HG are correlated with worse prognosis in patients with IDH-mutant leukemia, 79, 80 to our knowledge there appears to be no clear association between tumor D-2HG levels and outcome in patients with IDH-mutant glioma. Furthermore, the results of a recent study suggest that after an IDH-mutant tumor has been established, IDH-mutant activity and 2HG production may no longer be necessary for sustained tumor growth. 81 Therefore, targeting IDH-mutant neoenzymatic activity, particularly at the time of disease recurrence, may not work if these tumors are no longer IDHmutant-driven.
In addition to these concerns regarding the efficacy of targeting 2HG production, work by the Bindra laboratory recently demonstrated that elevated 2HG leads to the repressed ability of tumor cells to repair DNA by homologous recombination (HR). Indeed, these HR deficits could be recapitulated by engineering a heterozygous IDH1 mutation into an IDH wild-type cell line or by providing exogenous 2HG. 82 This HR deficiency renders IDH-mutant tumor cells more vulnerable to strategies that disrupt DNA repair. Consequently, blocking 2HG production with an IDH inhibitor reversed the repair deficits, thereby removing this vulnerability and potentially providing an advantage to the IDH-mutant tumor cells.
The identification of HR deficits in IDH-mutant cell lines and tumors has provided the opportunity for an alternative targeting strategy using poly(ADP-ribose) polymerase (PARP) inhibitors, based on the concept of synthetic lethality. In preclinical models, IDH1-mutant tumors and cell lines appear to be more sensitive to PARP inhibitors compared with equivalent IDH wild-type tumors and cell lines. 82 PARP inhibitors already have been approved for use in other cancer types, and a clinical trial investigating this class of drugs in IDH-mutant gliomas currently is in development.
Another line of investigation for the treatment of these tumors capitalizes on the G-CIMP epigenetic signature in IDH mutations. In light of data demonstrating the common hypermethylation patterns, many have wondered whether reversal of the aberrant methylation pattern can disrupt tumor growth. As a proof of concept, Turcan et al treated IDH-mutant glioma with the hypomethylating agent decitabine and found decreased proliferative potential in vitro and tumor stability in xenografts. 83 In addition, multiple groups have been investigating ways to use immunotherapy in the treatment of patients with IDH-mutant gliomas. One interesting strategy involves a vaccine using the tumor-specific IDH1 R132H antigen, which may have a reduced risk of generating an autoimmune response elsewhere in the body. An IDHmutant-specific peptide vaccine has been shown to generate an immune response in preclinical models 84 and slow tumor growth in a mouse glioma model. 85 An IDH1 R132H-mutant peptide vaccine currently is being investigated in a phase 1 clinical trial involving newly diagnosed grade II and grade IV IDH1-mutant gliomas (ClinicalTrial.gov identifier NCT02454634). In addition to the vaccine strategy, immune checkpoint inhibition with a programmed cell death protein 1 inhibitor currently is under investigation in patients with recurrent IDH-mutant grade II to IV gliomas whose tumors have a hypermutator phenotype, defined as harboring >30 mutations (ClinicalTrials.gov identifier NCT02658279). In addition, a phase 1 trial investigating the concurrent administration of the programmed death-ligand 1 inhibitor avelumab with hypofractionated RT currently is enrolling patients with IDH-mutant gliomas that have transformed into glioblastoma multiforme (ClinicalTrials.gov identifier NCT02968940). The rationale for these trials is based on data suggesting that gliomas that previously have been treated with alkylating agents such as TMZ and lomustine often develop a deficiency in DNA mismatch repair and consequently exhibit a higher mutational load. 28, [86] [87] [88] In turn, this increase in tumor mutations has been linked to elevated neoantigen generation and an improved response to immunotherapy. 89 Finally, as the field develops a deeper understanding of the metabolic dysregulation occurring in patients with IDH-mutant glioma, novel therapeutics capitalizing on these vulnerabilities may be on the horizon. Even with the many promising strategies that currently are emerging, designing optimal clinical trials in patients with newly diagnosed IDH-mutant glioma remains a challenge. The median OS of these patients is prolonged and therefore the use of progression-free survival and OS as endpoints leads to a prolonged follow-up period, sometimes lasting more than a decade. Proposed surrogate endpoints include radiologic response, tumor growth rates, and 2HG measurement by MRS. To the best of our knowledge, none of these surrogates has been fully or robustly characterized to date for control populations receiving standard treatment, particularly because consensus regarding standard treatment has been in flux and techniques such as 2HG measurement are new and still being optimized. Hopefully, innovation in this area will be forthcoming.
Conclusions
The realization that recurrent IDH mutations are ubiquitous among patients with low-grade glioma and in a subset of patients with glioblastoma has reshaped the way in which these tumors are viewed. There now is a greater appreciation that the biology of IDH-mutant glioma is quite different from that of IDH wild-type tumors, and that tumorigenic processes most likely are different as well. The discovery of the neoenzymatic function acquired by IDH-mutant tumors provides what to our knowledge is a first window into the mechanism of tumor formation and a wider appreciation of the critical role that metabolism plays in oncologic processes. D-2HG produced by a mutant IDH enzyme is believed to lead to changes in the epigenome of gliomas, triggering a cascade of aberrant cell signaling pathways that promotes proliferation, leads to changes in basal levels of key metabolites, and potentially disrupts DNA repair pathways. These recent insights into IDH-mutant glioma biology are paving the way for novel targeting strategies. However, there clearly still is much to be learned to develop efficient, targeted therapies to better treat these tumors.
FUNDING SUPPORT
No specific funding was disclosed.
